BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors. METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated. Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications. Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities. A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices. We identified 12 556 patients from 45 practices. The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%). The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment. CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting. Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.
BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors. METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated. Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications. Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities. A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices. We identified 12 556 patients from 45 practices. The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%). The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment. CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting. Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.
Authors: Robert O Bonow; Theodore G Ganiats; Craig T Beam; Kathleen Blake; Donald E Casey; Sarah J Goodlin; Kathleen L Grady; Randal F Hundley; Mariell Jessup; Thomas E Lynn; Frederick A Masoudi; David Nilasena; Ileana L Piña; Paul D Rockswold; Lawrence B Sadwin; Joanna D Sikkema; Carrie A Sincak; John Spertus; Patrick J Torcson; Elizabeth Torres; Mark V Williams; John B Wong Journal: Circulation Date: 2012-04-23 Impact factor: 29.690
Authors: Gregg C Fonarow; J Thomas Heywood; Paul A Heidenreich; Margarita Lopatin; Clyde W Yancy Journal: Am Heart J Date: 2007-06 Impact factor: 4.749
Authors: Charles N Kahn; Thomas Ault; Howard Isenstein; Lisa Potetz; Susan Van Gelder Journal: Health Aff (Millwood) Date: 2006 Jan-Feb Impact factor: 6.301
Authors: Paul S Chan; William J Oetgen; Donna Buchanan; Kristi Mitchell; Fran F Fiocchi; Fengming Tang; Philip G Jones; Tracie Breeding; Duane Thrutchley; John S Rumsfeld; John A Spertus Journal: J Am Coll Cardiol Date: 2010-06-29 Impact factor: 24.094
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2005-09-13 Impact factor: 29.690
Authors: Gregg C Fonarow; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mark L McBride; Patches Johnson Inge; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh; Clyde W Yancy Journal: Circulation Date: 2010-07-26 Impact factor: 29.690
Authors: Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Karen Pieper; Jie Lena Sun; Clyde W Yancy; James B Young Journal: Arch Intern Med Date: 2007-07-23
Authors: Michael L O'Byrne; Andrew C Glatz; Lihai Song; Heather M Griffis; Marisa E Millenson; Matthew J Gillespie; Yoav Dori; Aaron G DeWitt; Christopher E Mascio; Jonathan J Rome Journal: Circulation Date: 2018-11-06 Impact factor: 29.690
Authors: Prateeti Khazanie; Bradley G Hammill; Chetan B Patel; Michael S Kiernan; Lauren B Cooper; Suzanne V Arnold; Timothy J Fendler; John A Spertus; Lesley H Curtis; Adrian F Hernandez Journal: J Card Fail Date: 2016-02-15 Impact factor: 5.712
Authors: Michael L O'Byrne; Russell T Shinohara; Elena K Grant; Joshua P Kanter; Matthew J Gillespie; Yoav Dori; Jonathan J Rome; Andrew C Glatz Journal: Am Heart J Date: 2017-07-19 Impact factor: 4.749